

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/635,653 08/07/2003		Daopei Lu	077319-0373	8789	
22428	7590 01/22/2004		EXAMINER		
FOLEY AND LARDNER SUITE 500			PRYOR, ALTON NATHANIEL		
3000 K STRE	ET NW	ART UNIT	PAPER NUMBER		
WASHINGTON, DC 20007			1616		
			DATE MAILED: 01/22/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

124		Applicati	on No.	Applicant(s)				
Office Action Summary		10/635,6		LU, DAOPEI				
		Examine	r	Art Unit				
		Alton N. F		1616				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
	Responsive to communication(s) filed on <u>07</u>	August 2003	₹					
/—	This action is FINAL . 2b)⊠ This action is non-final.							
3)	-							
Disposition of Claims								
4)	4) Claim(s) 1-14,56 and 57 is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.							
6)□	5) Claim(s) <u>1-8,11-14,56 and 57</u> is/are rejected.							
7)	Claim(s) 9 and 10 is/are objected to.							
8)[8) Claim(s) are subject to restriction and/or election requirement.							
Applicati	on Papers							
9)☐ The specification is objected to by the Examiner.								
10) 🔲 .	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. §§ 119 and 120								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. 								
Attachment(s)								
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	··	4) Interview Summary (I 5) Notice of Informal Pa 6) Other:	PTO-413) Paper No(s) tent Application (PTO-				

Application/Control Number: 10/635,653

Art Unit: 1616

DETAILED ACTION

Objections – 37 CFR 1.75(c)

Claims 3,5 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. In a claim to a composition, a statement regarding the intended use of the composition has no patentable significance.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States

Claims 1-5,14 are rejected under 35 U.S.C. 102(b) as being anticipated by Yang et al (CN 1061908; 6/17/92). Yang teaches an anticancer drug comprising arsenic trioxide plus realgar (arsenic sulfide) plus a carrier (resin or alunite).

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Application/Control Number: 10/635,653

Art Unit: 1616

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-8,11-13 are rejected under 35 U.S.C. 102(e) as being anticipated by Ellison et al (US 2002/0183385; 12/5/02). Ellison teaches a composition comprising one or more arsenic compounds (arsenous sulfide, arsenic sulfide, arsenic pentasulfide, tetrasulfide, arsenic trioxide) in a carrier (saline solution, water) to be used in cancer treatment of mammals. See abstract, paragraphs 28,29,43,44,50,61,71,80. Ellison teaches that the composition is administered orally at a daily dosage of about 10Ug to 200 mg. See paragraph 63, claims 1-3,11,12.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 56,57 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ellison as applied to claims 108,11-13 above. See Ellison's 35 USC 102(b) rejection. Ellison teaches all that is recited in claims 56,57 except for the composition comprising the instant amount of arsenic sulfide. It would have been obvious to one having ordinary skill in the art to determine the optimum amount of arsenic sulfide. One would have been motivated to do this in order to develop a composition that would have been most effective in treating cancer.

Art Unit: 1616

Claim Objection

Page 4

Claims 9,10 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The prior art does not teach or suggest the invention comprising plant semen or semen platycladi.

Other Matters

Examiner suggests:

In claim 10 line 2 delete "seman" and insert --- semen ---.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 703 308-4691. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone number for the organization where this application or proceeding is assigned is 703 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

Alton Pryor

11 /my Primary Examiner